BankPlus Trust Department’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-400
Closed -$20.4K 479
2025
Q4
$20.4K Buy
+400
New +$20.5K 0.01% 323
2025
Q2
Sell
-132
Closed -$9.17K 470
2025
Q1
$9.17K Sell
132
-138
-51% -$11.4K ﹤0.01% 359
2024
Q4
$23.2K Buy
+270
New +$29.2K 0.01% 285

Other funds holding NVO

BankPlus Trust Department's NVO Position: Q1 2026 in Review

BankPlus Trust Department sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 400 shares — an estimated $20.4K sold.

BankPlus Trust Department first reported a position in NVO in Q4 2024 and held it in 3 quarters. The position peaked at $23.2K in Q4 2024. 1,277 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • BankPlus Trust Department reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • BankPlus Trust Department sold 400 Novo Nordisk shares in Q1 2026, an estimated $20.4K.
  • BankPlus Trust Department first reported a position in Novo Nordisk in Q4 2024 and held it in 3 quarters.
  • BankPlus Trust Department's Novo Nordisk position peaked at $23.2K in Q4 2024.
  • 1,277 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on BankPlus Trust Department's 13F filing for Q1 2026, filed 11 May 2026.